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Abstract
Background: Grass carp reovirus (GCRV) is the causative pathogen of grass carp hemorrhagic disease, one of the
major diseases damaging grass carp Ctenopharyngon idellus breeding industry in China. Prevention and control of
the disease is impeded largely due to the lack of research in economic subunit vaccine development. This study
aimed to evaluate the potential of viral outer shell protein VP5 as subunit vaccine.
Methods: The vp5 gene was isolated from the viral genome through RT-PCR and genetically engineered to
express the recombinant VP5 protein in E coli. The viral origin of the recombinant protein was confirmed by
Western blot analysis with a monoclonal antibody against viral VP5 protein. Polyclonal antibody against the
recombinant VP5 protein was prepared from mice. A microneutralization assay was developed to test its
neutralizing ability against GCRV infection in cell culture.
Results: The GST-VP5 fusion protein (rVP5) was produced from E. Coli with expected molecular weight of 90 kDa.
The protein was purified and employed to prepare anti-VP5 polyclonal antibody from mice. The anti-VP5 antibody
was found to neutralize GCRV through in vitro microneutralization assay and viral progeny quantification analysis.
Conclusions: The present study showed that the viral VP5 protein was involved in viral infection and bacterially-
expressed VP5 could be suitable for developing subunit vaccine for the control of GCRV infection.
Background
Reoviruses are distributed widely in aquatic environ-
ments and have been isolated from a wide range of
aquatic organisms. Grass carp reovirus (GCRV) is cur-
rently one of the most serious pathogens threatening
the grass carp Ctenopharyngon idellus production with
high mortality in China [1]. The virions consist of a
double-layered protein capsid containing 11 dsRNA
genomic fragments [2]. GCRV was assigned to the
genus Aquareovirus of the family Reoviridae by the
international committee on Taxonomy of Viruses
(ICTV) in 1991 [3]. It differed from orthoreovirus in a
number of characteristics such as absence of an
antigenic relationship and unequal numbers of genome
segments [4]. To improve the production of grass carp
and reduce the economic losses, effective vaccine against
GCRV is urgently desired for the fish cultivation indus-
try. However, functional characterization of the encod-
ing proteins of GCRV has been limited due to the lack
of research interest of GCRV in regions outside of
China. Besides this, the majority of human orthoreovirus
infections involve the gastrointestinal and upper respira-
tory, which are generally asymptomatic [5]. The majority
of adults have neutralizing antibodies and no preventa-
tive vaccination is needed for the viral infection. Thus,
although extensive studies have been conducted on the
replication of mammalian reovirus in host cells, little
effort has been made to test the vaccine potential of its
structural proteins. Fully attenuated apathogenic avian
reovirus vaccine did have been developed by serial
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fibroblast cultures [6,7]. Outer capsid Sigma C protein
had been implicated for the use of potential subunit vac-
cine against avian reovirus infection [8]. Until now, the
only commercial carp vaccine in Asia is an inactivated
grass carp reovirus vaccine [9]. Traditional methods,
such as attenuation of wild-type viruses to generate live
vaccines and formalin-inactivation to produce killed vac-
cine, are still being employed to develop effective pre-
v e n t i v es t r a t e g ya g a i n s tG C R Vi nC h i n a[ 1 0 ] ;t h e
unpopular application of these vaccines at present indi-
cates that further improvement of vaccines in terms of
safety, efficacy, manufacturing cost, and field manipula-
tion is essential for the disease control. New advances in
molecular biology and biotechnology of virus could help
us understand which viral factors are important for
induction of strong immunity and lead to new strategies
of vaccine design [11].
Identification and production of protective antigens is
probably the most feasible strategy towards low-cost
vaccines for low-price grass carp. The core of GCRV is
c o m p o s e do ff i v ep r o t e i n s :V P 1 ,V P 2 ,V P 3 ,V P 4a n d
VP6 [12]. A total of 120 VP3 molecules form the spheri-
cal inner capsid shell of the GCRV inner core. The
outer capsid of GCRV was composed of 200 trimers of
VP5-VP7 heterodimers, which were analogous to the
μ13s33 complexes of well-characterized mammalian reo-
virus but with significant differences in protein structure
and low homology. VP7 only shares a very low sequence
identity of 12% with its counterpart s3o fM a m m a l i a n
reovirus, while the identity between VP5 and μ1 is 24%
[13]. The outer capsid proteins of both mammalian reo-
virus and GCRV were involved in host recognition and
attachment during viral replication although not
required for efficient viral replication inside the host
cells [14,15]. The function of VP7 is unclear at present,
while the overall similar structure between VP5 and μ1
suggests a similar functional role of cell membrane
penetration during viral entry into host cells for both
proteins [13]. Polyclonal antibodies against μ1a n ds3
were reported able to neutralize Mammalian reovirus
in vitro [14]; thus, among all the five viral structural
proteins, VP5 was selected to test its subunit vaccine
potential against GCRV in this report.
The aim of present study was to evaluate the potential
of VP5 protein as subunit vaccine against GCRV infec-
tion through employing in vitro microneutralization
assays, which has been used successfully for the measure-
ment of neutralizing antibodies to various viruses in vac-
cine and epidemiologic studies [16]. Information derived
from such assays formed the basis for passive immuniza-
tion strategies against virus infection [17,18]. The investi-
gation also present information on the basic role of VP5
protein in the initial steps of GCRV infection.
Results
Expression, purification and immunoblotting analysis of
recombinant VP5 protein (rVP5)
To produce rVP5 in E. coli, the vp5 gene fragment of
1947 bp was isolated through RT-PCR from the purified
viral dsRNA genome (Figure 1a). The PCR product was
then inserted to the bacterial expression vector
pGEX3T-4 for the expression of a GST-VP5 fusion pro-
tein, the correct clone bearing the indeed vp5 gene was
confirmed by gene sequencing. Expected GST-VP5
fusion protein of about 90 KDa could be induced by
IPTG in cultured bacterial (Figure 1b). The expression
level of rVP5 was about 10% of the total bacterial pro-
tein. The IPTG-induced protein of 50 ng/μl was isolated
from the gel for the use of purified antigen to develop
polyclonal antibodies against VP5 (Figure 1b). The viral
origin of the induced and purified rVP5 was confirmed
by immunoblotting assay with a specific monoclonal
antibody against viral VP5 protein (Figure 1c).
Specificity of polyclonal antibody against GCRV virions
To prepare polyclonal antibodies against GCRV VP5
protein, the purified rVP5 was injected into the mice as
described in the Materials and Methods. However, it
was unclear whether the rVP5 sustained the same anti-
genicity as viral VP5 protein. Thus, the raised polyclonal
antibodies were pooled together, named as anti-VP5
here, for the determination of its specificity toward
GCRV viral particles by immunoblotting assay. Figure 2
showed that the pooled polyclonal antibody recognized
the viral VP5 protein as revealed by the positive signal
at the expected size of about 67 KDa. In contrast, the
control serum contained no antibody to recognize viral
VP5 protein in the immunoblotting assay (Figure not
shown).
Microneutralization assay and virus titration
The above results indicated that anti-VP5 polyclonal
antibody was able to recognize the viral VP5 protein,
but it remained to know whether it contained antibodies
that could block the virus infection for evaluation of the
potential of rVP5 as subunit vaccine. For this purpose, a
microneutralization assay was employed to check the
neutralizing ability of the anti-VP5 polyclonal antibody.
For more accuracy, the serum dilution was tested in
four replicate wells per dilution (Figure 3a). Based on
the visual assay result, the neutralization titer of the
tested antibody was 1:40.
To confirm the neutralization result, the supernatant of
infected cells in the 96 well plate was collected for viral
titration assay. Low viral progeny of 10
2-10
3 TCID50/ml
was observed for the wells infected with GCRV mixed
with anti-VP5 sera of 1:20 or 1:40 dilution; while the
viral production reached 10
7 TCID50/ml for the cells
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1:80 to 1:2560 dilution (Figure 3b).
Discussion
Grass carp Ctenopharyngon idellus culture is an impor-
tant economic industry for China, which has suffered
from GCRV-induced hemorrhagic disease for some
years [19]. Although whole virus-inactivated vaccine had
been applied in some fish farms for the prevention of
the disease, more efficient and economic vaccine
approaches were urgently desired for the national-wide
control of the viral disease. Subunit vaccine presents an
ideal promise for this purpose. The present study aimed
to identify the subunit vaccine potential of outer shell
protein VP5. As the outer shell protein, VP5 might have
key effects on the viral infection, such as recognition
and attachment to receptors in the host cell surface, as
well as penetration into the host cell membrane during
the virus assembly [20]. The fact that anti-VP5 polyclo-
nal antibodies efficiently blocked viral infection here
supported that VP5 was involved in viral infection, and
posed as a good candidate for the development of subu-
nit vaccine.
The availability of a stable grass carp cell line CIK
cells and the strong CPE induced by GCRV infection
p a v e dt h ew a yf o rt h ee s t a b l i s h m e n to fa nin vitro neu-
tralization assay. For the visual microneutralization
assay, an optimal working dilution of 50 TCID50 virus in
50 μl volume per well was determined in a preliminary
logarithmic serial dilution tests. It ensured observable
CPE within 48 h postinfection under light microscope
in contrast to the uninfected cells. The stained signal of
cells in the 96 well plate irreversibly correlated well with
the virus-induced CPE for the low dilution of sera (1:20-
1:80), which validated the method for neutralization
assay. However, for the sera of high dilution (1:160 -
1:2560), the difference of stained signal was not signifi-
cant, which was reasonable due to the fact that
un-neutralized virus replicated quickly in CIK cells. We
didn’t optimize the production procedure of anti-VP5
antibody from mice in this study. The low neutralizing
titer of 1:40 might be largely due to the low titer of
anti-VP5 polyclonal antibody raised from mice. To
further validate the visual neutralization assay, virus
end-point titers were calculated using TCID50 assay.
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Figure 1 Cloning, expression, purification and immunoblotting assay of rVP. a, the 1% agarose gel electrophoresis of vp5 gene fragment
amplified from GCRV genome by RT-PCR. b, 10% SDS-PAGE analysis of induced and purified rVP5. c, Immunoblotting assay of rVP5 with
monoclonal antibody against VP5 protein. Second antibody was the HRP-conjugated goat-anti-mouse (Sigma). M, Protein marker; U, total cell
extract of uninduced bacterial; I, total cell extract of IPTG-induced bacterial; P, purified rVP5.
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Figure 2 Immunoblotting assay of GCRV virions with
polyclonal antibody anti-VP5. Mock-infected CIK cell lysate from
10
5 cells (lane 1), purified GCRV viral particles of 1 μg (lane 2) and
GCRV-infected CIK cell lysate from 10
5 cells (lane 3) were subjected
for 10% SDS-PAGE analysis and transferred to PVDF membrane. The
first antibody used here was the pooled antisera collected from the
immunized mice. Second antibody was the HRP-conjugated goat-
anti-mouse (Sigma).
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tested well correlated very well with the amount of CPE
as showed by the reduction of stained signal of the cell
monolayer. It was worthy to note that, in the microneu-
tralization assay, the continued presence of antibody
through the course of the assay could neutralize virus
released from infected cells.
As far is known, this is the first report on designing a
microneutralization assay to test neutralization antibo-
dies against GCRV. The assay could test antibody sam-
ples with high throughput since the cell culture, viral
infection and staining were all performed in a 96-well
format. For further in vivo animal experiments to test
the protective effect of rVP5 protein, the microneutrali-
zation assay on a large scale could still be valuable in
addressing the protection mechanism on how and when
the neutralization antibody was produced in individual
immunized animal. This assay could also be employed
for mapping neutralizing epitope of VP5 protein for
immunological characterization purpose.
In summary, the gene of GCRV outer shell protein
VP5 was cloned and efficiently expressed in Ec o l i .t o
get recombinant protein antigen rVP5, an in vitro
microneutralization assay was developed to show that
polyclonal antibody against rVP5 was able to block viral
infection. The results support the idea that a subunit
vaccine based on the rVP5 was possible for the control
of GCRV infection in Grass carp Ctenopharyngon
idellus.
Methods
Virus culture
Grass carp Ctenopharyngon idellus kidney cells (CIK)
were maintained in DMEM medium with 10% fetal
bovine serum [21](Zuo et al., 1984). Grass carp reovirus
873 strain (prototype strain) from CCTCC (China center
for type culture collection) was used in the study. To
propagate the virus, monolayers of CIK were infected
with GCRV and incubated for 2-3 days at 28°C. Infected
supernatants or cells were harvested when greater than
90% CPE (Cytopathic effect) was observed.
Viral RNA extraction and RT-PCR reaction
Culture supernatant (250 ml) containing GCRV virions
were collected and centrifuged at 60,000 × g for 1 h
(SW41 rotor, Beckman). Genomic dsRNA was then
extracted from the purified GCRV using a Trizol method
(Invitrogen). The dsRNA was separated from contaminat-
ing ssRNA by precipitating in 2 M lithium chloride
(LiCl). The dsRNA was resuspended in DEPC-treated
water and stored at -80°C until use. The reverse tran-
scription was performed with the reverse transcription kit
(Takara) using the extracted viral genome template and
random primer according to the manufacture’s protocol.
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Figure 3 Neutralization of GCRV by anti-VP5 polyclonal antibody. a, Microneutralization assay. The anti-VP5 polyclonal antibody was tested
for four repeats here (Lane 1-4). 50 TCID50 virus was used for the assay in Lanes 1-4 and Lane 6. Dilution of anti-VP5 serum was as indicated in
the figure (Lanes 1-4), with the diluted preimmunized sera served as control sera here (Lane 6). Mock infected cells with diluted control sera
served as positive control (Lane 5). b, Virus titration assay. The supernantant of each tested well was subjected for TCID50 assay. The data
represents the mean value of the four repeats of tested well for each dilution of anti-VP5; the data of Serum control represents the mean value
of the 8 test wells served as positive control, in which the control serum was mixed with 50 TCID50 virus in the microneutralization assay.
Standard deviation of each representative data was as indicated in the chart.
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transcriptase reaction mixture at 42°C for 60 min and
stopped by the addition of 0.5 M EDTA, pH8.0. The
cDNA was used directly for PCR amplification of vp5
gene using Master PCR system (Takara). Vp5 gene
was amplified through PCR using primer pairs of
TCCCCCGGGGGATGGGGAACGTTCAAACCTCCGT
and ATAAGAATGCGGCCGCTTATCACTTGCCGGG
CCACAA from the viral genome cDNA mix. Amplifica-
tion was carried out after denaturation at 94°C for 2 min,
followed by 30 cycles of denaturation for 15 s at 95°C,
annealing for 30 s at 62°C, extension for 2 min at 68°C
and a final extension step for 10 min at 72°C. After
sequence confirmation, the vp5 gene fragment was
digested by Sma I and Not I before inserting into the
corresponding restriction sites of pGEX4T-3 (GE Health-
care) to get recombinant plasmid pGEX-vp5.
Expression of recombinant VP5 protein and Western blot
assay
To express VP5 as glutathione (GST) fusion protein by
pGEX-vp5 in DH5a, 100 ml of Luria-Bertani medium
containing 100 μg ampicillin/ml was inoculated with 1/
100 of an overnight culture containing either of the
recombinant plasmids and grown to an optical density
of 0.6 at 600 nm. Protein expression was induced with 1
mM IPTG (isopropyl-b-D-thiogalactopyranoside) for 3
h. The bacteria were collected at 6000 × g for 10 min,
and the pellet was resuspended in 5 ml of PBS. Protein
expression level was judged by SDS-PAGE, through
which the ChemiDoc™XRS+ system (Bio-Rad) was
employed for the automated quantitative analysis of
stained protein samples on PAGE gel. The specificity
and viral origin of expressed protein was further ana-
lyzed by Western Blot assay using specific monoclonal
antiserum again VP5, which was commercially devel-
oped using standard methods by injection of specific
peptide sequence (291aa-305aa: PRSYRPAFIKPEDAK)
of VP5 into mouse at the antibody production facility in
A b M a r t ,C h i n a .F o rW e s t e r nb l o t s ,p r o t e i n sw e r e
resolved by SDS-PAGE and transferred to PVDF
(Biorad) using standard methods. After blocking in 4%
milk and binding of primary antibodies, membranes
were washed extensively and incubated with anti-mouse
IgG conjugated to alkaline phosphatase. Signal was
development by using BCIP and NBT substrates
(Sigma).
Purification of VP5 protein and preparation of polyclonal
antibody
The insoluble debris containing the GST-VP5 fusion
protein was collected by centrifugation at 5,000 g and
washed three times using PBS. Then the total insoluble
protein was subjected to SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) analysis, then cut from the
gel and used for protein purification with PAGE gel pro-
tein recovery kit (Sangon Biotech). To generate specific
polyclonal antisera towards VP5, groups of 4 adult
(6 weeks old) female Balb/c mice were intraperitoneally
immunized in a 50% emulsion of Freud’sa d j u v a n tw i t h
50 μg of purified recombinant VP5 protein, and boosted
twice at 3 weeks interval with the same doses. Immune
sera were collected 7 days after the last immunization.
Pre-immune serum was collected before immunization
and used as a control in neutralization experiments.
Immunoglobulin (IgG) antibodies were purified by pro-
tein A-sepharose (Promega) and stored at -20°C. Both
pre-immune sera and immunized sera were pooled
together in the study, which were named as serum con-
trol and anti-VP5 serum respectively.
TCID50 (50% tissue culture infective dose) assay
The GCRV titer was determined as TCID50 on CIK cells
based on a typical cytopathic effect produced by viral
infection [22]. CIK cells were maintained as stock cul-
tures in DMEM and re-plated 2 days before infection
with GCRV in 96 well plates for TCID50 assay. The
virus stock was serially diluted with DMEM and then
used for infection of CIK. Cell cultures were infected for
1 h, and fed with 200 μl fresh medium. 48 h post infec-
tion, 96 well plates were observed under light miscope
for typical CPE. The TCID50 value was calculated using
Reed Muench method.
Microneutralization assay
The in vitro microneutralization assay was performed
according to a modified protocol [23]. Cells infected
with 50 TCID50 v i r u sa n dc e l l sw i t hm o c ki n f e c t i o n
served as positive and negative controls in the assay
respectively. The assay medium for serum and virus
dilution was the complete growth medium for CIK cells.
The sera were inactivated at 56°C for 30 min and seri-
ally diluted twofold in a microtiter plate with 50 μlp e r
well. Six serial 2-fold dilutions (1:20 - 1:2560) of serum
i nav o l u m eo f5 0μl were loaded into the plate wells,
followed by the addition of 50 TCID50 virus. The plates
w e r ei n c u b a t e da t2 8 ° Cf o r1 h. During the incubation
period, CIK cells were trypsinized and resuspended at 5
×1 0
4 cells per ml. Cell suspension (100 μl per well) was
added to the plates, the solutions were mixed, and the
plates were incubated at 28°C for 48 h. Cells in the 96
well plate were then stained with the dye crystal violet
(5% in PBS), which stains only living cells here. If a
serum sample contains antibodies that block viral infec-
tion, most of the cells will survive and present violet
color; if the virus can’t be blocked by the serum, cells
will be infected, round up and detach from the cell cul-
ture plate, thus no violet staining is visible for infected
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cal of the highest dilution at which virus infection is
blocked.
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